tbuckley/cabot-search huggingface dataset:
Cardiovascular health‐related quality of life in cancer: a prospective study comparing the <scp>ESC HeartQoL</scp> and <scp>EORTC QLQ‐C30</scp> questionnaire
Authors: Markus S. Anker, Sophia K. Potthoff, Alessia Lena, Jan Porthun, Sara Hadzibegovic, Ruben Evertz, Corinna Denecke, Ann‐Kathrin Fröhlich, Frederike Sonntag, Vera Regitz‐Zagrosek, Stuart D. Rosen, Alexander R. Lyon, Thomas F. Lüscher, John A. Spertus, Stefan D. Anker, Mahir Karakas, Lars Bullinger, Ulrich Keller, Ulf Landmesser, Javed Butler, Stephan von Haehling
Journal: European Journal of Heart Failure (2023)

Health-related quality of life (HRQoL) is highly relevant in cancer and often assessed with the EORTC QLQ-C30. Cardiovascular HRQoL in cancer can be measured with the ESC HeartQoL questionnaire. We compared these instruments and examined their prognostic value.Summary scores for EORTC QLQ-C30 (0-100 points) and ESC HeartQoL (0-3 points) questionnaires were prospectively assessed in 290 patients with mostly advanced cancer (stage 3/4: 81%, 1-year mortality: 36%) and 50 healthy controls (similar age and sex). Additionally, physical function and activity assessments were performed. Both questionnaires demonstrated reduced HRQoL in patients with cancer versus controls (EORTC QLQ-C30: 67 ± 20 vs. 91 ± 11, p < 0.001; ESC HeartQoL: 1.8 ± 0.8 vs. 2.7 ± 0.4, p < 0.001). The instruments were strongly correlated with each other (summary scores [r = 0.76], physical [r = 0.81], and emotional subscales [r = 0.75, all p < 0.001]) and independently associated with all-cause mortality (best cut-offs: EORTC QLQ-C30 <82.69: hazard ratio [HR] 2.33, p = 0.004; ESC HeartQoL <1.50: HR 1.85, p = 0.004 - adjusted for sex, age, left ventricular ejection fraction, N-terminal pro-B-type natriuretic peptide [NT-proBNP], high-sensitivity troponin T, cancer stage/type), with no differences in the strength of the association by sex (p-interaction > 0.9). Combining both questionnaires identified three risk groups with highest mortality in patients below both cut-offs (vs. patients above both cut-offs: HR 3.60, p < 0.001). Patients with results below both cut-offs, showed higher NT-proBNP and reduced physical function and activity.The EORTC QLQ-C30 and ESC HeartQoL - assessing cancer and cardiovascular HRQoL - are both associated with increased mortality in cancer patients, with even greater stratification by combing both. Reduced HRQoL scores were associated with elevated cardiovascular biomarkers and decreased functional status.
Association of Ambient Temperature With the Prevalence of Intimate Partner Violence Among Partnered Women in Low- and Middle-Income South Asian Countries
Authors: Yixiang Zhu, Cheng He, Michelle Bell, Yuqiang Zhang, Zafar Fatmi, Ying Zhang, Maryam Zaid, Jovine Bachwenkizi, Cong Liu, Lu Zhou, Renjie Chen, Haidong Kan
Journal: JAMA Psychiatry (2023)

Intimate partner violence (IPV), including physical, sexual, and emotional violence, constitutes a critical public health problem, particularly in low- and middle-income countries. While climate change could escalate violent events, data quantifying its possible association with IPV are scant.
Coronary Atherosclerotic Plaque Activity and Future Coronary Events
Authors: Alastair Moss, Marwa Daghem, Evangelos Tzolos, Mohammed N. Meah, Kang-Ling Wang, Anda Bularga, Philip D. Adamson, Jacek Kwiecinski, Alison Fletcher, Dana Dawson, Parthiban Arumugam, Nikant Sabharwal, John P. Greenwood, Jon N. Townend, Patrick A. Calvert, James H. F. Rudd, Dan Berman, Johan Verjans, Piotr Slomka, Damini Dey, Laura Forsyth, Lauren Murdoch, Robert J. Lee, Steff Lewis, Nicholas L. Mills, Edwin J. R. van Beek, Michelle C. Williams, Marc R. Dweck, David E. Newby, Anny Briola, Ruth Armstrong, Alix Macdonald, Gill Scott, Garry Milne, Lynsey Milne, Claire Battison, Martin R Wilkins, Robert F Storey, Reza Razavi, Maja Wallberg, Rodney Mycock
Journal: JAMA Cardiology (2023)

Recurrent coronary events in patients with recent myocardial infarction remain a major clinical problem. Noninvasive measures of coronary atherosclerotic disease activity have the potential to identify individuals at greatest risk.
Doxorubicin‐Loaded Microrobots for Targeted Drug Delivery and Anticancer Therapy
Authors: Sudipta Mallick, Ramadan Abouomar, David Rivas, Max Sokolich, Fatma Ceren Kirmizitas, Aditya Dutta, Sambeeta Das
Journal: Advanced Healthcare Materials (2023)

Micro-sized magnetic particles (also known as microrobots [MRs]) have recently been shown to have potential applications for numerous biomedical applications like drug delivery, microengineering, and single cell manipulation. Interdisciplinary studies have demonstrated the ability of these tiny particles to actuate under the action of a controlled magnetic field that not only drive MRs in a desired trajectory but also precisely deliver therapeutic payload to the target site. Additionally, optimal concentrations of therapeutic molecules can also be delivered to the desired site which is cost-effective and safe especially in scenarios where drug dose-related side effects are a concern. In this study, MRs are used to deliver anticancer drugs (doxorubicin) to cancer cells and subsequent cell death is evaluated in different cell lines (liver, prostate, and ovarian cancer cells). Cytocompatibility studies show that MRs are well-tolerated and internalized by cancer cells. Doxorubicin (DOX) is chemically conjugated with MRs (DOX-MRs) and magnetically steered toward cancer cells using the magnetic controller. Time-lapsed video shows that cells shrink and eventually die when MRs are internalized by cells. Taken together, this study confirms that microrobots are promising couriers for targeted delivery of therapeutic biomolecules for cancer therapy and other non-invasive procedures that require precise control.
Driving Diversity and Inclusion in Cancer Drug Development – Industry and Regulatory Perspectives, Current Practices, Opportunities, and Challenges
Authors: Lola A. Fashoyin-Aje, Craig Tendler, Bea Lavery, Serban Ghiorghiu, Brittany Gerald, Chitkala Kalidas, Nicole Richie, Kathleen Winson, Nicholas J.H. Warren, Tristen V. Tellman, Jon Retzlaff, Margaret Foti, Richard Pazdur
Journal: Clinical Cancer Research (2023)

Abstract In April 2022, the FDA issued draft guidance to help industry develop strategies to improve diversity in clinical trials. Historically, clinical trial sponsors have not systematically incorporated efforts to promote diversity, equity, and inclusion (DEI), particularly during the early design stages of clinical development plans and operational strategies. Unfortunately, a retrospective approach to DEI often results in clinical trial participants not being reflective of the diversity of patients intended to be treated with new therapies. A shift to prospective, intentional DEI strategies for clinical trials, including long-term engagement with diverse patients and communities throughout the development life cycle, is necessary to maximize the benefits and minimize the risks of new drugs and devices for all patients. Sponsors’ current practices and opportunities for improving DEI address four major topics: institutional commitment, culture change, and governance; clinical development strategy; setting enrollment goals to ensure trial participant diversity; and development and implementation of the operational strategy. As DEI practices gain wider adoption in clinical trials, shared learning and collaboration among stakeholders on an ongoing and noncompetitive basis will lead to sustainable change. Prioritization of enrollment of diverse populations as an integral part of study start-up planning, clinical trial design, and recruitment capabilities will enhance the clinical development process for oncology therapies. Importantly, these efforts will help provide equitable access to clinical trials and innovative cancer therapies.
Treatment-Resistant Edematous Annular Plaques and Mild Leukopenia in a Man in His 60s
Authors: Philipp W. Raess, Merav Sendowski, Nicole Fett
Journal: JAMA Dermatology (2023)

A man in his 60s presented with a 5-year history of diffuse erythematous, edematous annular plaques, low-grade fevers, and mild leukopenia. What is your diagnosis?
Chemotherapy-Induced Pseudocellulitis Without Prior Radiation Exposure
Authors: Leah D. Kovacs, Michaela O’Donoghue, Anna L. Cogen
Journal: JAMA Dermatology (2023)

Importance Chemotherapy-induced pseudocellulitis is an ill-defined term for a poorly understood phenomenon. Encompassing a myriad of cellulitis-mimicking oncologic adverse cutaneous drug reactions (ACDRs), pseudocellulitis may be difficult to diagnosis, and the lack of treatment guidance may mean unnecessary antibiotic exposure and interruptions to oncologic care. Objectives To use case reports to characterize the various cellulitis-mimicking reactions caused by chemotherapeutic medications, to understand how these reactions affect patient care (ie, antibiotic exposure and interruptions to oncologic treatment), and to make recommendations for improved diagnosis and care of patients with chemotherapy-induced pseudocellulitis. Evidence Review A systematic review of case reports of patients with pseudocellulitis was performed. Reports were identified through database searches using PubMed and Embase, with subsequent reference searches. Included publications described at least 1 case of chemotherapy-induced ACDR and used the term pseudocellulitis or showed evidence of cellulitis mimicry. Cases of radiation recall dermatitis were excluded. Data were extracted from a total of 32 publications representing 81 patients diagnosed with pseudocellulitis. Findings Of the 81 cases (median [range] age, 67 [36-80] years; 44 [54%] male patients), most were associated with gemcitabine use; pemetrexed use was reported less frequently. Only 39 were considered to be true chemotherapy-induced pseudocellulitis. These cases resembled infectious cellulitis and did not meet diagnostic criteria for any known diagnoses; therefore, these were described solely as pseudocellulitis. Of this group, 26 patients (67%) had been administered antibiotics before the correct diagnosis was made, and 14 patients (36%) experienced interruptions to their oncologic treatment plans. Conclusions and Relevance This systematic review found a variety of chemotherapy-induced ACDRs that mimic infectious cellulitis, including a group of reactions termed pseudocellulitis that do not meet criteria for other diagnoses. A more universally accepted definition and clinical research on chemotherapy-induced pseudocellulitis would allow for more accurate diagnosis, effective treatment, antibiotic stewardship, and continuation of oncologic treatment.
Testosterone Therapy Did Not Increase Major Cardiovascular Events
Authors: Emily Harris
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nutritional Supplements and Hair Loss—Limitations to the Interpretation of Clinical Studies Before Implementation in Clinical Practice
Authors: Luigi Naldi, Ignacio Garcia-Doval, Hywel C. Williams
Journal: JAMA Dermatology (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Comments on the myPACE Randomized Clinical Trial
Authors: Massimiliano Camilli, Roberto Scacciavillani, Filippo Crea
Journal: JAMA Cardiology (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Enhancing Partnerships of Institutions and Journals to Address Concerns About Research Misconduct
Authors: Susan Garfinkel, Sabina Alam, Patricia Baskin, Christina Bennett, Bridget Carruthers, Jeffrey Engler, Annette Flanagin, Sheila Garrity, Chris Graf, Michael J. Imperiale, Christopher King, Sabine Kleinert, Dan Kulp, Courtney Mankowski, Nicola Nugent, Teodoro Pulvirenti, Lauran Qualkenbush, Emily Sobiecki, Daniel Wainstock, Erica Wilfong, Loren Wold, Jennifer Yucel
Journal: JAMA Network Open (2023)

Institutions and journals strive to promote and protect the integrity of the research record, and both groups are equally committed to ensuring the reliability of all published data.Three US universities coordinated a series of virtual meetings from June 2021 to March 2022 for a working group composed of senior, experienced US research integrity officers (RIOs), journal editors, and publishing staff who are familiar with managing issues of research integrity and publication ethics. The goal of the working group was to improve the collaboration and transparency between institutions and journals to ensure that research misconduct and publication ethics are managed properly and efficiently. Recommendations address the following: identifying proper contacts at institutions and journals, specifying information to share between institutions and journals, correcting the research record, reconsideration of some fundamental research misconduct concepts, and journal policy changes. The working group identified 3 key recommendations to be adopted and implemented to change the status quo for better collaboration between institutions and journals: (1) reconsideration and broadening of the interpretation by institutions of the need-to-know criteria in federal regulations (ie, confidential or sensitive information and data are not disclosed unless there is a need for an individual to know the facts to perform specific jobs or functions), (2) uncoupling the evaluation of the accuracy and validity of research data from the determination of culpability and intent of the individuals involved, and (3) initiating a widespread change for the policies of journals and publishers regarding the timing and appropriateness for contacting institutions, either before or concurrently under certain conditions, when contacting the authors.The working group recommends specific changes to the status quo to enable effective communication between institutions and journals. Using confidentiality clauses and agreements to impede sharing does not benefit the scientific community nor the integrity of the research record. However, a careful and informed framework for improving communications and sharing information between institutions and journals can foster better working relationships, trust, transparency, and most importantly, faster resolution to data integrity issues, especially in published literature.
Influenza vaccination and cardiovascular events in patients with ischaemic heart disease and heart failure: A meta‐analysis
Authors: Daniel Modin, Mats Christian Højbjerg Lassen, Brian Claggett, Niklas Dyrby Johansen, Maryam Keshtkar‐Jahromi, Kristoffer Grundtvig Skaarup, Joshua Nealon, Jacob A. Udell, Orly Vardeny, Scott D. Solomon, Gunnar Gislason, Tor Biering‐Sørensen
Journal: European Journal of Heart Failure (2023)
Mitochondrial GSNOR Alleviates Cardiac Dysfunction via ANT1 Denitrosylation
Authors: Xin Tang, Shuang Zhao, Jieqiong Liu, Xiameng Liu, Xinqi Sha, Changgao Huang, Lulu Hu, Shixiu Sun, Yuanqing Gao, Hongshan Chen, Zhiren Zhang, Dongjin Wang, Yuexi Gu, Shaoliang Chen, Liansheng Wang, Aihua Gu, Feng Chen, Jun Pu, Xin Chen, Bo Yu, Liping Xie, Zhengrong Huang, Yi Han, Yong Ji
Journal: Circulation Research (2023)

The cardiac-protective role of GSNOR (S-nitrosoglutathione reductase) in the cytoplasm, as a denitrosylase enzyme of S-nitrosylation, has been reported in cardiac remodeling, but whether GSNOR is localized in other organelles and exerts novel effects remains unknown. We aimed to elucidate the effects of mitochondrial GSNOR, a novel subcellular localization of GSNOR, on cardiac remodeling and heart failure (HF).
Nutritional Supplements and Hair Loss—Limitations to the Interpretation of Clinical Studies Before Implementation in Clinical Practice
Authors: Chinemelum Obijiofor, Christine C. Akoh, Kristen Lo Sicco
Journal: JAMA Dermatology (2023)

To the Editor We read with great interest the systematic review by Drake et al1 that evaluated research regarding the efficacy of nutritional supplements for hair loss. We recognize additional considerations that were not highlighted in the review as limitations.
Estimated Prevalence of Perinatal Depression in Low- and Middle-Income Countries Considering Uncertainty of Test Properties
Authors: João Pedro Gonçalves Pacheco, Giovanni Salum, Maurício Scopel Hoffmann
Journal: JAMA Psychiatry (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients
Authors: Anna Giuliano, Barbara Kuter, Shari Pilon‐Thomas, Junmin Whiting, Qianxing Mo, Brett Leav, Bradley Sirak, Christopher Cubitt, Christopher Dukes, Kimberly Isaacs‐Soriano, Kayoko Kennedy, Somedeb Ball, Ning Dong, Akriti Jain, Patrick Hwu, Jeffrey Lancet
Journal: Cancer Communications (2023)

Abstract Background Compared to the general population, cancer patients are at higher risk of morbidity and mortality following SARS‐CoV‐2 infection. The immune response to a two‐dose regimen of mRNA vaccines in cancer patients is generally lower than in immunocompetent individuals. Booster doses may meaningfully augment immune response in this population. We conducted an observational study with the primary objective of determining the immunogenicity of vaccine dose three (100 μg) of mRNA‐1273 among cancer patients and a secondary objective of evaluating safety at 14 and 28 days. Methods The mRNA‐1273 vaccine was administered ∼7 to 9 months after administering two vaccine doses (i.e., the primary series). Immune responses (enzyme‐linked immunosorbent assay [ELISA]) were assessed 28 days post‐dose three. Adverse events were collected at days 14 (± 5) and 28 (+5) post‐dose three. Fisher exact or X 2 tests were used to compare SARS‐CoV‐2 antibody positivity rates, and paired t ‐tests were used to compare SARS‐CoV‐2 antibody geometric mean titers (GMTs) across different time intervals. Results Among 284 adults diagnosed with solid tumors or hematologic malignancies, dose three of mRNA‐1273 increased the percentage of patients seropositive for SARS‐CoV‐2 antibody from 81.7% pre‐dose three to 94.4% 28 days post‐dose three. GMTs increased 19.0‐fold (15.8‐22.8). Patients with lymphoid cancers or solid tumors had the lowest and highest antibody titers post–dose three, respectively. Antibody responses after dose three were reduced among those who received anti‐CD20 antibody treatment, had lower total lymphocyte counts and received anticancer therapy within 3 months. Among patients seronegative for SARS‐CoV‐2 antibody pre‐dose three, 69.2% seroconverted after dose three. A majority (70.4%) experienced mostly mild, transient adverse reactions within 14 days of dose three, whereas severe treatment‐emergent events within 28 days were very rare (&lt;2%). Conclusion Dose three of the mRNA‐1273 vaccine was well‐tolerated and augmented SARS‐CoV‐2 seropositivity in cancer patients, especially those who did not seroconvert post–dose two or whose GMTs significantly waned post–dose two. Lymphoid cancer patients experienced lower humoral responses to dose three of the mRNA‐1273 vaccine, suggesting that timely access to boosters is important for this population.